Neurology Live: The Complexities of Alzheimer Disease Treatment and Diagnosis in Clinical Trials: Sharon L. Rogers, PhD

The Complexities of Alzheimer Disease Treatment and Diagnosis in Clinical Trials: Sharon L. Rogers, PhD The chief executive officer at AmyriAD Therapeutics discussed the limitations of clinical trials assessing potential disease-modifying therapies for Alzhiemer disease including the lack of a diverse patient population and nonthorough clinical assessments for diagnosis. The current available treatments for patients…

Sitting Down With… Sharon L Rogers, AmyriAD CEO, Renowned drug developer, 2023 Power Lister, and Olympic figure skating official

Fabulously Interesting Sitting Down With… Sharon L Rogers, AmyriAD CEO, Renowned drug developer, 2023 Power Lister, and Olympic figure skating official. What inspired you to pursue a career in your field? Between undergraduate and graduate school, I was working at the Ohio State University in Columbus in a laboratory studying viral-chemical co-carcinogenesis related to asbestos.…

Neurology Live: The Potential of AD101 for Managing Symptoms of Alzheimer Disease

The Potential of AD101 for Managing Symptoms of Alzheimer Disease Aug 1, 2023 Isabella Ciccone, MPH Sharon L. Rogers, PhD, chief executive officer at AmyriAD Therapeutics, discussed AD101, a novel drug that targets the core symptoms in Alzheimer disease, and highlighted the importance of symptom management strategies. AD101 (AmyriAD) is an innovative small molecule influencing…

Conversations Life Science Leaders Aren’t Having: Perspectives on Healthcare Leadership and Patient-Centricity – with Sharon Rogers

In this episode, we sit down with Sharon Rogers, the CEO of Amyriad Therapeutics, a leading company in the fight against Alzheimer’s Disease. Their dedication to developing innovative therapies is making a profound impact on patients’ lives. Sharon’s journey is truly inspiring. From founding her first business in college to a remarkable 35-year career in…

Moving Beyond Amyloid in Alzheimer’s Therapeutics

April 18, 2023 A growing number of start-up companies are pursuing alternative strategies in drug development for patients with Alzheimer’s disease that bypass the beta amyloid hypothesis that has dominated the field for decades. Although the major manifestations of AD are global cognitive decline and loss of independent function, accessory symptoms include aberrant accumulation of…